ALLEGRA MEDICAL TECHNOLOGIES LIMITED Allegra Medical Technologies Limited Stock
Equities
AMT
AU000000AMT8
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.029 AUD | +26.09% |
|
-.--% | -35.56% |
| Mar. 22 | Allegra Medical Technologies Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| Mar. 11 | Trading in Allegra Medical Technologies' Stock Could Resume on March. 25 | MT |
| Sales 2022 | 3.93M 2.52M | Sales 2023 | 691K 444K | Capitalization | 5.75M 3.69M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -1.28M | Net income 2023 | -3M -1.92M | EV / Sales 2022 | 5.33 x |
| Net Debt 2022 | 2.13M 1.36M | Net Debt 2023 | 3.13M 2.01M | EV / Sales 2023 | 12.8 x |
| P/E ratio 2022 |
-7.41
x | P/E ratio 2023 |
-1.57
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 17.54% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +26.09% | ||
| 3 months | -34.09% | ||
| 6 months | -51.67% | ||
| Current year | -35.56% |
Current year
0.02
0.05
1 year
0.020.08
3 years
0.020.33
5 years
0.020.84
10 years
0.020.84
| Managers | Title | Age | Since |
|---|---|---|---|
Jenny Swain
CEO | Chief Executive Officer | - | 11-02-13 |
Vincent Wang
DFI | Director of Finance/CFO | - | 15-12-31 |
Katy Mitchell
LAW | General Counsel | - | 18-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Kazacos
CHM | Chairman | - | - |
Sean Mulhearn
BRD | Director/Board Member | - | 15-11-16 |
| Director/Board Member | - | 18-03-06 |
Allegra Medical Technologies Limited, formerly Allegra Orthopaedics Limited, is a biotechnology company. The Company is engaged in the medical device industry with its pioneering three dimensional (3D)-printed Sr-HT and Sr-HT-Gahnite orthopedic devices. It holds exclusive ownership of bio ceramic material, along with registered patents and patent applications from the University of Sydney. This material has several applications, including its use as a cervical fusion cage in spinal surgery, offering treatment options for patients. The Company is developing Sr-HT ceramic material to demonstrate the bioactivity required for bone regeneration. Sr-HT-Gahnite features bioactivity, biocompatibility, and mechanical properties suitable for load- bearing orthopedic implants. The primary focus centers on commercializing the Sr-HT Gahnite Bone substitute.
Calendar
2024-08-29
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -35.56% | 2.23M | |
| -2.53% | 183B | |
| -3.52% | 105B | |
| +5.33% | 51.77B | |
| +16.43% | 47.29B | |
| -1.73% | 40.2B | |
| +5.66% | 27.62B | |
| -2.01% | 25.51B | |
| +9.84% | 24.73B | |
| -1.87% | 24.52B |
- Stock Market
- Equities
- AMT Stock
